We have examined the restriction map of the c-myc gene in 15 BL cell lines carrying the variant t(8;22) transiocation in which c-myc is known to remain on chromosome 8. Using 3 restriction enzymes cutting outside the c-myc domain (EcoRI, BamHI, Hindlll), we found no evidence for a c-myc/Ig lambda rearrangement in 14 BL cell lines. In the last one, BL 37, the 3' flanking region was rearranged corresponding to the already identified breakpoint located 400 pb downstream from the c-myc gene (9)-Using 4 restriction enzymes cutting inside the c-myc gene (PvuII, PstI, Sad, Hindi) we looked for discrete abnormalities within the gene limits, and we found in 9 BL cell lines several abolished and created sites, compatible with multiple independent somatic mutations. They are significantly clustered in the 5' non coding region, with a striking prevalence at the end of exon 1. The role of mutations in the non-coding first exon region for the deregulation of c-myc expression is discussed.
IHTRODUCTIOH
Chromosomal translocations bringing together the c-myc oncogene and an immunoglobulin (Ig) domain are a characteristic and constant feature of occurs in the 5' region of c-myc, at several possible sites, suggesting that the gene disruption itself directly affects some regulatory elements. In all cases c-myc is translocated to chromosome 14. In the variant translocations, t(2;8) and t (8;22) , in contrast, c-myc remains on chromosome 8, and a C region of a light chain Ig gene is fused downstream (3') of c-myc, usually at a considerable distance (10 to 100 kb) (5) (6) . This raises the challenging question of how c-myc can be deregulated by a remote event.
In the present study, we have analysed a large number of BL cell lines with the t(8;22) variant transiocation, to look systematically for somatic mutations and see whether they cluster In a given region of the c-myc gene.
As an alternative to the cloning and sequencing of DNA from each case, we scanned the 8 kb domain comprising the entire c-myc gene by a number of restriction enzymes and probed the resulting fragments with a battery of overlapping probes. This enabled us to find many somatic mutations occurring significantly in and around the first exon of an otherwise non-disrupted c-myc gene.
MATERIALS AND METHODS

Cell lines
Fifteen Burkitt cell lines with fully documented (8; -a control LCL established by EBV from a subject without Burkitt (LL84) and having already undergone more than 100 cell divisions.
DNA analysis
Genomic DNA was phenol extracted from frozen cell pellets, digested by one of the following restriction endonucleases : EcoRI, BamHI, Hindlll, PvuII, PstI, Sad, Hindi, electrophoresed in 0.6 to 1.0 % agarose and blotted on nylon membrane (Zetabind, Blorad) as described by Southern (7).
Hybridization was carried out for 20 h at 55° C (final wash), and exposed to Kodak X Omat AR5.
Probes
Several genomic probes covering altogether the entire c-myc domain were used (see fig 1) . These probes explored all the sites existing for the 1 enzymes used.
Sometimes a same site was explorable with two adjacent probes (fig 1) .
Sequence of c-mye and normal restriction sites
The precise location of the restriction sites of the enzymes used in the study was computed from the 8 kb long Hind III-EcoRI fragment sequenced by
Gazin et al (8) . It extends from 2303 nucleotides upstream exon I (Hindlll site) to 869 nucleotides downstream exon 3 (EcoRI site).
All "cryptic" site3, le sites in which a single base substitution can generate a new 6 nucleotide sequence recognized by each of the restriction enzymes used, were also computed.
RESULTS
Restriction map with enzymes cutting outside the c-nyc gene :
Restriction fragments obtained by EcoRI (12.5 kb), Hindlll (11.5 kb) and BamHI, (ca 26 kb) digestion allow the exploration of the "whole" c-myc gene.
In 13 out of 15 Burkitt cell lines with t(8;22) the c-myc restriction pattern was normal, indicating that no gross rearrangement of c-myc, as could be produced by the nearby transposition of a lambda Ig gene, had occurred.
In BL 37 an abnormal pattern of the 3' site was detected (data not shown), corresponding to the rearrangement of this region with a lambda constant Ig gene already described by Hollis et al (9) .
In BL 101 the size of the Hindlll and BamHI fragments were apparently unmodified. Using EcoRI we found, in addition to the normal 12. These results were systematically confirmed using several consecutive probes, (table II) .
In the BL 101 cell line, in which an additional EcoRI site was found in lntron 1, all the other explored sites (PvuII, Sad, Hindi, and PstI) in that region were normal. These results confirm that this EcoRI site is not due to a c-myc Ig rearrangement at a chromosomal breakpoint, but is a new created site in the 360 bp interval between unperturbed PvuII-Xbal sites.
Using probe 1 the 3' flanking region of c-myc was also explored by PvuII (0.7 kb 3' of EcoRI site) and Pst I (6.5 kb 3' of EcoRI site) (not shown in The mutated sites are not randomly distributed on the whole c-myc region explored. Altogether ( fig. 1 and H, table II) in the 9 BL cell lines we found 6 abnormalities upstream exon 1, 7 abnormalities in exon 1 (all consisting in the abolition of the same PvuII restriction site near the end of exon 1, at position 513). 11 abnormalities in intron 1, 2 abnormalities in exon 2 and none in exon 3 and in the 3' flanking sequence of the gene. Interestingly, whereas the amount of cryptic sites is higher in exon 2 + intron 2, the created sites occurred preferentially in the 5' non-coding half of the c-myc gene (fig 1 and 4) .
Search for restriction aap abnormalities of c-myc in non BL cells
To exclude the possibility that some restriction site modifications could be actually due to RFLPs, we analysed, with the same enzymes and probes, DNA from peripheral leukocytes of 11 normal unrelated individuals. We failed to detect any perturbation at the sites that had been found abnormal in the BL cell lines. In addition (i) the constitutional DNA from LCL established from 1.7.
figure 3 :
Absence of mutated restriction sites in lymphoblastoid cell lines derived from peripheral blood of BL subjects compared to their BL cell line counterpart. IARC 3O<4 is the LCL of the BL 2 subject, IARC 261 and 277 derive from the BL 60 subject. Saol digested DNA was hybridized with c-myc exon 2 probe (SacI -SacI probe n° 3). peripheral blood of subjects BL 2, BL 37, BL 60 and BL 10^ did not display any of the abnormal patterns found in their corresponding BL cell line DNA ( fig 3) ; (ii) the restriction map of c-myc in the DNA from control LCL which had undergone more than 100 cell divisions was also normal. (table II) .
As to the created sites, assuming that they originated by a single base change, we searched for all existing "cryptic" sites exhibiting only one difference with the 6 nuoleotide sequence specific for each restriction enzymes. As seen in fig H 186 such sites pre-exist. Since they are almost evenly distributed all through there was no bias introduced by our choice of enzyme and the observed clustering of the created sites is not circumstancial.
Also if a bias against mutations occurring in the exons is conceivable, the tolerance of mutations should be the same in the two introns and their distribution in both introns should be equal. This is not the case : no abnormal site was found in intron 2, whereas altogether 11 abnormal sites were found in intron 1.
Because the few selected enzymes explore only few existing site transcriptional down regulation mechanism has been recently suggested (29, 30) . The mutation we found are precisely clustered around the boundary of exon 1 and intron 1, a region which is believed to be essential for transcriptional arrest (30) . In particular the PvuII 3ite at the end of exon I is part of a proposed stem and loop structure which might act as a transcription termination signal (30) . A partial or complete constitutive release of this block might be produced by point mutations, leading to the deregulation of c-myc. The fact that in our series of BL with t(8;22) the PvuII mutation was strikingly prevalent in African subjects (6 out of 6), as compared with European cases (1 out of 9), is compatible with the existence of more than one mechanism of deregulation of the c-myc gene even when it is not translocated.
